MPS Pharmaa Faces Evaluation Adjustment Amid Financial Strain and Low Investor Confidence
MPS Pharmaa, a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently experienced a score revision due to a decline in its quality grade. The company faces financial challenges, including negative net debt and a low return on capital employed, alongside bearish technical indicators and low institutional holding.
MPS Pharmaa, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment, reflecting a revision in its score. This change is primarily attributed to a shift in its quality grade, which now indicates below-average performance. Key financial metrics reveal that MPS Pharmaa has faced challenges in several areas. The company has reported negative net debt and a tax ratio that is negative, suggesting potential financial strain. Additionally, the return on capital employed (ROCE) stands at -16.00%, indicating inefficiencies in generating returns from its capital investments. The company's institutional holding is notably low at 0.58%, which may reflect a lack of confidence among larger investors.
In terms of technical indicators, the stock's trend has shifted to bearish, with various metrics such as MACD and Bollinger Bands signaling a downward trajectory. The stock's recent performance has been marked by a significant decline from its 52-week high of 4.33, now trading at 2.08.
Overall, the evaluation adjustment for MPS Pharmaa underscores the company's current market position and the underlying trends affecting its financial health.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
